News
Entertainment
Science & Technology
Life
Culture & Art
Hobbies
News
Entertainment
Science & Technology
Culture & Art
Hobbies
Humans Make the Game: What Baseball’s Tech Debate Can Teach Healthcare About the Value of Connection - MedCity News
Healthcare, like baseball, is ultimately a human experience. And no matter how advanced the tools, patients still want to feel something real: that someone sees them, hears them, and cares.
With Drug Picked Up From Sanofi, Startup AllRock Takes Aim at Two Severe Lung Diseases - MedCity News
AllRock Bio’s drug is a small molecule pan-ROCK inhibitor ready for Phase 2 testing in pulmonary arterial hypertension and pulmonary hypertension with interstitial lung disease. The startup is led by the management team that steered CinCor Pharma to a $1.3 billion acquisition by AstraZeneca.
Harbor Health Secures $130M To Grow Insurance Plans and Clinical Footprint - MedCity News
Harbor Health's funding was co-led by General Catalyst, 8VC and Alta Partners. The round also includes participation from Dell Family Office Management, Health 2047 Capital Partners, Lemhi Ventures, Martin Ventures and Breyer Capital.
Beyond Politics: Payer Solutions for Fluoride-free Communities - MedCity News
This isn’t a political issue, it’s a public health challenge with real consequences for kids’ futures. As reality sets in, we must face the possibility of a post-fluoridation era and find new ways to give kids in at-risk communities a fair shot at a healthy smile.
MedCity Pivot Podcast: Price Transparency is the New North in the PBM World - MedCity News
In this episode, a pharmacy benefit management executive and a pharmacy startup talk about why benefit verification, prior authorizations, and patient affordability still break the workflow and how smart integrations, real-time eligibility, and intuitive design can reduce friction for all involved.
How HBO’s Emmy-Winning Drama Captures the Chaos Hospitals Workers Face - MedCity News
HBO’s The Pitt won three Emmys for its portrayal of the challenges faced by healthcare workers. Dr. Jason Cohen, a physician and chief medical officer of inpatient at patient flow automation startup Qventus, said the series highlights critical issues like emergency department boarding, staffing shortages and the mental toll on patient care and frontline staff.
Novartis Adds to Its Immunology Prospects With Another Deal for Monte Rosa’s Molecular Glue Drugs - MedCity News
Novartis is paying $120 million up front to secure rights to a Monte Rosa molecular glue degrader drug candidate as well as options for two others. The two companies began working together last year under an alliance focused on immune mediated-diseases.
Industry Groups Warn CMS’ 2026 Fee Schedule Could Undermine Value-Based Care - MedCity News
Healthcare groups are pushing back on CMS’ proposed physician fee schedule for next year, raising concerns over payment cuts, administrative burdens and mandatory participation in a new value-based model. Organizations including MGMA, NAACOS and Premier are calling on the agency to revise its plan.
Maze Therapeutics Drug Shows Potential to Top Asset Acquired by Otsuka for $800M - MedCity News
With positive Phase 1 results for the metabolic disorder drug MZE782, Maze Therapeutics plans to advance the small molecule to Phase 2 tests in phenylketonuria and chronic kidney disease. Following the data readout, Maze raised $150 million in a private placement.
Microplastics Are in Our Blood — Why Aren’t Federal Regulators Acting? - MedCity News
The longer we delay, the further we shift costs from polluters to patients — and to every taxpayer who funds Medicare, Medicaid and community hospitals. Environmental stewardship and human health are inseparable; regulating microplastics is preventive medicine on a national scale.
Penguin Ai Snags $30M to Simplify Prior Auth, Coding and Claims - MedCity News
Penguin Ai raised $29.7 million for its AI platform aimed at automating costly administrative tasks like prior authorization and medical coding. CEO Fawad Butt said the startup’s goal is to move beyond point solutions and create an “Epic of the healthcare back office.”
Long Regulatory Saga for Intercept Pharma Liver Drug Ends a Decade After Speedy FDA Approval - MedCity News
Intercept Pharmaceuticals is voluntarily withdrawing from the market Ocaliva, a drug for the rare liver disease primary biliary cholangitis. While Ocaliva became an important new treatment option when it won accelerated FDA approval in 2016, PBC patients now have new FDA-approved medicines from Ipsen and Gilead Sciences that don’t pose the same safety risks.
Inside the Clinical Decision Support Market: The Race to Make AI Work at the Point of Care - MedCity News
The clinical decision support market is evolving quickly. With heavy investor backing and competing strategies around specialization, data depth and distribution, the coming years will determine which companies emerge as lasting leaders at the point of care.
LB Pharma Pushes the Biotech IPO Window Open, Bagging $285M for Key Schizophrenia Drug Trial - MedCity News
LB Pharmaceuticals found enough investor interest to boost the size of its IPO, which will finance clinical trials in schizophrenia and bipolar depression. The biotech has modified an old Sanofi drug with changes intended to reduce side effects and allow less frequent dosing.
Healthcare's Data Orchestra: Why Rising Drug Denials Signal a Need for Better Coordination - MedCity News
The real story isn’t about denial rates or stakeholders acting as villains. It’s about a healthcare system that forces intelligent, well-intentioned professionals to make critical decisions in information silos.
Racing the Clock: The Life-or-Death Power of Early Drugs-of-Abuse Diagnostics in the Emergency Department - MedCity News
Early diagnostics for acute intoxication in the emergency department are about more than just identifying the cause of an overdose. They can enable timely intervention, reduce the risk of fatal outcomes, and open the door to substance use disorder treatment and recovery
Positioning & Distribution Will Determine the Winning Healthcare AI Startups, Investor Says - MedCity News
In a crowded healthcare AI market, the winners will be those that control key leverage points — where data is created, workflows are streamlined and value is delivered across stakeholders. This will differentiate winning AI startups from incumbents and copycat competitors, said Morgan Cheatham, head of healthcare and life sciences at Breyer Capital.
FDA Nod for J&J’s Drug/Device Treatment Gives Bladder Cancer Patients Another Option - MedCity News
A Johnson & Johnson cancer treatment that can spare certain bladder cancer patients from the radical step of surgical removal of the organ now has FDA approval. J&J’s drug/device combination product, Inlexzo, came from the 2019 acquisition of Taris Biomedical.
Novartis’s $1.4B Tourmaline Acquisition Brings Heart Drug That Could Rival Novo Nordisk, CSL Meds - MedCity News
Novartis is getting Tourmaline Bio’s pacibekitug, a Phase 3-ready antibody drug in development for atherosclerotic cardiovascular disease (ASCVD). Tourmaline licensed pacibekitug from Pfizer, which remains eligible for milestone payments tied to the progress of the drug.
Corewell Health Touts Success of Virtual Lifestyle Medicine Program with Nudj Health - MedCity News
Corewell Health is seeing positive results from its partnership with Nudj Health, a startup that delivers virtual lifestyle medicine programs. More than 3,600 Corewell patients have enrolled in Nudj’s programs since 2023 — and their reported improvements include weight loss, reduced depression and anxiety levels, better cholesterol and triglyceride levels, and increased daily exercise minutes.
SOAR Act Would Help Individuals Relying on Oxygen Thrive - MedCity News
The bill clarifies very specific patient protections and codifies a Patient’s Bill of Rights, all of which would ensure that individuals receiving supplemental oxygen in the home – and their suppliers – understand requirements around equipment, communications, and care options.